Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hereditary Angioedema (Mar 2017)

Posted by Matt Breese on Mar 22, 2017

Find me on:

According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past quarter reflects some shifts in 2017 plan year formularies. Medicare formularies were impacted most with an increase in restrictions that made-up for any lift we saw in Q4.The percentage of multiple product steps and restrictive-to-label PA policies also increased.

mmit-reality-check-hae-q1.png

Source: MMIT data as of Q1 2017

Trends:  Recent news related to HAE treatments highlights some key trends in this therapeutic area. A handful of hereditary angioedema launches reveals the shift in drug development from manufacturers. Novel therapies incite increased prophylaxis utilization. Additionally, the recent launch of an HAE treatment for pediatric patients provides some additional options for prescribers.

In the full Reality Check on HAE treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on hereditary angioedema with key findings on clinical characteristics, HAE drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

 

Topics: Specialty, Market Access, Branding & Marketing